ReviewFrontiers in pharmacology2025
Neuroprotective mechanisms of Buyang Huanwu decoction in ischemic stroke.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quantitative analysis of Chinese herbal medicine for post-stroke fatigue: a meta-analysis and medication pattern study.Frontiers in pharmacology · 2026Pooled it
- Study on the Mechanism of Buyang Huanwu Decoction in Treating Ischemic Stroke by Regulating the NLRP3/Caspase-1 Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke (IS) continues to be a major contributor to global mortality and long - term disability. Buyang Huanwu Decoction (BHD), a traditional Chinese medicine formula, has shown effectiveness in reducing brain injury and promoting post - stroke recovery through experimental researches and clinical trials. The neuroprotective mechanisms of BHD against cerebral ischemic injury involve multiple pathways, such as suppression of inflammation, reduction of oxidative stress, inhibition of apoptosis, regulation of autophagy, and enhancement of mitochondrial function. Moreover, BHD presents therapeutic potential by boosting neuroplasticity, enhancing angiogenesis, reducing excitotoxicity, optimizing brain energy metabolism, and regulating gut microbiota. Considering the current scarce effective treatments for IS, exploring BHD's therapeutic potential and its mechanism holds substantial clinical significance. This review systematically organizes recent research advancements on BHD's application in IS management and its underlying mechanisms, providing useful insights for future research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.